‘We’ll save the world from cancer’: Inside Pfizer CEO’s $23 billion post-COVID bet on oncology

"The winners in life are differentiated from the losers in life because the winners never fall," Albert Bourla says. "The ...

Pfizer: A High-Yield Pharma At A Turning Point

Pfizer Inc. has a 6% yield and 8.49x P/E with new cancer drugs and GLP-1 therapies to offset 2026-2028 LOE cycles. Read why ...

Pfizer CEO took on COVID. Now he wants to cure cancer | Titans and Disruptors

Dr. Albert Bourla became Pfizer’s CEO months before the COVID-19 pandemic took hold of the US. Under his leadership, Pfizer manufactured 3 billion doses of the first FDA-approved vaccine in the first ...
Nasdaq

Pfizer and BioNTech’s COMIRNATY® Receives U.S. FDA Approval for Adults 65 and Older and Individuals Ages 5 through 64 at Increased Risk for Severe COVID-19

The 2025-2026 COVID-19 vaccine formulation targets the SARS-CoV-2 sublineage LP.8.1, in line with FDA guidance to more closely match circulating strains1 Shipping of the LP.8.1-adapted vaccine will ...

Pfizer CEO says he used ‘emotional blackmail’ to get employees to achieve impossible goals during COVID-19

Albert Bourla admitted to going to extreme lengths to “save the world” and get the vaccines out faster during the COVID-19 ...

Pfizer’s CEO on leading after a moonshot—and making deals with Trump

In today’s CEO Daily: Fortune Editor-in-Chief Alyson Shontell interviews Pfizer CEO Albert Bourla. The big story: Target’s ...